pediatric acute lymphoblastic leukemia
Conditions
Interventions
pre-emptive pharmacogenetic testing group:In the 6-MP precision dosing regimen, pediatric hematology-oncology ward based clinical pharmacists deliver ward-based pharmaceutical care by helping clinicia
Sponsors
Fujian Children's Hospital
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Participants involved in pediatric leukemia treatment and willing to be interviewed: (1) Pediatric hematology-oncology physicians; (2) Pediatric hematology-oncology ward-based clinical pharmacists; (3) Clinical laboratory physicians; (4) Representatives from third-party genetic testing companies; (5) Administrative staff from the hospital's medical insurance office; (6) Guardians of pediatric hematology-oncology patients. 2. Patients receiving preemptive pharmacogenetic testing: (1) Pediatric patients with newly diagnosed ALL who require treatment with 6-MP, aged 1-18 years; (2) Receiving at least one cycle of HD-MTX infusion and oral 6-MP treatment.
Exclusion criteria
Exclusion criteria: 1. Pediatric acute lymphoblastic leukemia patients with liver and kidney function exceeding 5 times of the baseline.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical outcome effectiveness;Reach;Adoption;Fidelity;Maintenance; | — |
Countries
China
Contacts
Public ContactRong Hu
Fujian Children's Hospital
Outcome results
None listed